1. Introduction {#Sec1}
===============

Worldwide, colorectal cancer is the fourth most common neoplasm in men and the third most common in women.\[[@CR1]\] Although mortality rates from the disease in South America remain among the lowest in the world, a recent trend towards increasing mortality due to colorectal cancer has been seen in Mexico, Brazil, Chile, and Ecuador.\[[@CR1]\] The majority of colorectal cancer cases arise from an adenomatous polyp, which progresses into advanced adenoma with high-grade dysplasia, and finally transforms into invasive cancer.\[[@CR2]\] The appearance of polyps and subsequent transformation into cancerous lesions may involve both genetic and environmental factors. Colorectal cancer that is localized within the colon or has only spread to the lymph nodes is curable by surgery with or without chemotherapy, and has a 5-year survival rate of 44--93%.\[[@CR3]\] However, cancer that has metastasized to distant sites is generally incurable and has a 5-year survival rate of \<10%.\[[@CR3]\]

Twenty-five years ago, few physicians were optimistic about the chances of progress in the treatment of colorectal cancer and for improved survival for patients with this disease. However, over the last decade or so, survival rates of patients with metastatic colorectal cancer have increased from 5 months with best supportive care\[[@CR4]\] to almost 2 years with combination chemotherapy with fluorouracil (5-FU), leucovorin plus irinotecan plus bevacizumab ([figure 1](#Fig1){ref-type="fig"}).\[[@CR7]\] Throughout this time, a growing body of evidence has developed to support the importance of vascular and nutritional support for the survival of the tumor, and has ultimately led to the development of agents such as bevacizumab, which work through disruption of tumor blood flow by decreasing angiogenesis. This review is based on a series of meetings of an opinion and analysis panel in Mexico City in September 2009, and discusses a number of important issues in the treatment of colorectal cancer, including the use of prognostic and predictive biomarkers, the optimum treatment of metastatic disease, and resection of hepatic metastases.

![Median overall survival following first-line treatment for metastatic colorectal cancer.\[[@CR4]--[@CR10]\] 5-FU = fluorouracil; **BEV** = bevacizumab; **FOLFIRI** = irinotecan plus infusional fluorouracil/leucovorin; **FOLFOX** = oxaliplatin plus infusional fluorouracil/leucovorin; **IFL** = irinotecan plus bolus fluorouracil/leucovorin; **LV** = leucovorin.](40268_2012_11020101_Fig1){#Fig1}

2. Predictive and Prognostic Biomarkers in Colorectal Cancer {#Sec2}
============================================================

A number of prognostic and predictive indicators are used to guide therapy in patients with colorectal cancer, and the difference between the two types of markers is an important distinction to make. A prognostic marker is indicative of patient survival independent of treatment, whereas a predictive marker is indicative of therapeutic efficacy.

Colorectal cancer may arise from two distinct mutational pathways. Approximately 15% of tumors display microsatellite instability (MSI) mutations, giving rise to a phenotype of tumors termed high-frequency MSI (MSI-H).\[[@CR11]\] However, the majority (∼85%) of colorectal cancers arise through chromosomal instability and have genetic alterations involving loss of heterozygosity, chromosomal amplifications, and chromosomal translocations.\[[@CR11]\] These tumors, termed microsatellite-stable (MSS) tumors, present and behave in a similar way to low-frequency MSI (MSI-L) tumors. Compared with MSS and MSI-L tumors, MSI-H tumors are more frequently right-sided, high-grade, and mucinous types.\[[@CR11]\] They are also likely to have a larger primary tumor at diagnosis, but are more frequently node negative. Patients with MSI-H tumors have a better long-term prognosis compared with similarly staged MSS tumors. MSI might be a predictive marker, as patients with MSI-H colon cancers gain no benefit from 5-FU-based adjuvant chemotherapy.\[[@CR12]\]

Elevated carcinoembryonic antigen (CEA) prior to surgical resection is a poor prognostic indicator; a serum level of 5 ng/mL is considered a standard cut-off.\[[@CR13]\] While in the past CEA levels have been used in conjunction with overall stage to define a subset of patients in whom postoperative chemotherapy is required, current guidelines recommend that CEA only be used to indicate disease recurrence following resection.\[[@CR14]\] Abnormalities of the tumor suppressor gene *p53*, situated on chromosome 17p, are associated with the development of colorectal cancer, but the current value of using *p53* as a prognostic marker in colorectal cancer is unclear.\[[@CR11]\] For example, an increased risk of mortality was seen with the presence of *p53* mutation in resected stage II and III colon cancer in a retrospective review.\[[@CR11]\] However, expression of *p53* was associated with favorable survival in stage III but not stage II disease in a study by the Southwest Oncology Group.\[[@CR15]\]

The RAS and RAF families of proteins act as transducers and integrators of signals from a number of surface growth factors with downstream effects on subsequent transducers, such as PI3K and MAPK. Mutations of *KRAS* occur in approximately 40% of colorectal cancer specimens,\[[@CR16]\] and although these mutations do not appear to be a prognostic factor in colorectal cancer, they do confer resistance to epidermal growth factor receptor (EGFR)-targeted therapy. For example, in the CRYSTAL trial (see [table I](#Tab1){ref-type="fig"} for full trial names), in which patients with metastatic EGFR-expressing colorectal cancer received irinotecan plus infusional 5-FU/leucovorin (FOLFIRI) with or without cetuximab, the benefit of the anti-EGFR monoclonal antibody was confined to patients without *KRAS* mutations.\[[@CR17]\] Based on these and other findings, the European Medicines Agency approved the EGFR inhibitor panitumumab for use in patients with wild-type *KRAS* only.\[[@CR18]\] *BRAF* mutations occur less frequently, but are also associated with reduced response to EGFR inhibitors. The *BRAF-V600E* mutation, in particular, impairs the therapeutic effects of cetuximab and panitumumab.\[[@CR19]\] Consensus guidelines recommend that the presence of *KRAS* mutations be determined in all patients diagnosed with stage IV colorectal cancer.\[[@CR14]\]

![Trial names](40268_2012_11020101_Tab1){#Tab1}

There are currently no suitable predictive biomarkers for bevacizumab treatment.\[[@CR20]--[@CR23]\]

It was originally thought that markers of tumor angiogenesis could be used to predict clinical outcome to bevacizumab therapy; however, vascular endothelial growth factor (VEGF) expression and microvessel density do not predict treatment outcome in patients with colorectal cancer.\[[@CR22]\] In addition, thrombospondin expression within the tumor does not predict response to bevacizumab.\[[@CR22]\]

Angiopoietin-2 is a key regulator of VEGF function,\[[@CR24]\] and Goede et al.\[[@CR25]\] investigated whether angiopoietin-2 was a candidate biomarker for predicting outcome in patients with metastatic colorectal cancer treated with bevacizumab. Serum angiopoietin-2 was significantly elevated in patients with metastatic colorectal cancer versus healthy subjects. Patients with stage IV colorectal cancer had significantly higher serum angiopoietin-2 levels versus patients with stage I--III colorectal cancer or healthy controls (3.9 vs 2.3 ng/mL, p = 0.001; and 3.9 vs 2.4 ng/mL, p = 0.006, respectively). Low serum angiopoietin-2 levels were associated with a significantly better response rate (82% vs 31%; p \< 0.01) compared with high serum angiopoietin-2 levels in patients receiving bevacizumab-based regimens. A prolonged median progression-free survival (14.1 vs 8.5 months; p \< 0.01) and a 91% reduction in death (p \< 0.05) was also observed.\[[@CR25]\]

In a phase II study examining the efficacy of FOLFIRI plus bevacizumab in patients previously untreated for metastatic colorectal cancer, elevated baseline interleukin-8 levels were associated with a shorter median progression-free survival (11 vs 15.1 months; p = 0.03).\[[@CR26]\] Basic fibroblast growth factor, placental growth factor, and hepatic growth factor were all elevated before disease progression.\[[@CR26]\]

Further investigation into the predictive molecular markers for clinical outcome to bevacizumab is required.

3. Angiogenesis and Vascular Endothelial Growth Factor {#Sec3}
======================================================

Blood vessels supplying tumors have a number of abnormalities in their structure and function.\[[@CR27]\] Like normal blood vessels, those in solid tumors are composed of endothelial cells, mural cells, and a basement membrane. However, tumor vessels exhibit abnormalities in each of the structural components.\[[@CR27]\] In addition, they are irregularly shaped, poorly organized, and lack the arteriole-capillary-venule hierarchy. The secretion of certain factors alters the balance between endothelial cell proliferation and apoptosis, resulting in increased cell division and stimulation of the formation of new vessels through angiogenesis.\[[@CR28],[@CR29]\] Co-option of existing blood vessels or incorporation of bone marrow progenitor cells into existing vessels also increases tumor blood supply.\[[@CR30]\] Structural abnormalities of the endothelial layer of tumor blood vessels reduce normal barrier function and make them prone to leaking.\[[@CR31]\] This increases interstitial fluid pressure, compromising blood flow to the affected area, and has implications for drug delivery to the tumor.\[[@CR32]\] Impaired barrier function also increases the extravasation of tumor cells, and thus metastasis and growth factors produced or released by blood monocytes/macrophages contribute to tumor progression.\[[@CR27],[@CR33]\] This impaired endothelial function increases the risk of hemorrhage in the tumor and has implications for patients undergoing surgery.\[[@CR27]\]

VEGF is highly expressed on the endothelial cells of blood vessels supplying tumors and promotes the growth of endothelial cells in arteries, veins, and lymphatic vessels.\[[@CR34]\] In addition, it stimulates angiogenesis *in vivo*,\[[@CR35]\] promotes vascular permeability and capillary leak,\[[@CR36]\] and induces the expression of molecules that control the adhesion of leukocytes in models of inflammation.\[[@CR37]\] These effects occur through binding of VEGF to VEGF receptor-2 (also known as Flk-1 or KDR).\[[@CR38]\] Bevacizumab is a humanized monoclonal antibody that binds to and neutralizes VEGF-A. It has a half-life of approximately 17--21 days and does not elicit an antibody response in clinical trials.\[[@CR39]\] Bevacizumab has been investigated for the treatment of a range of tumor types and is an important factor in the treatment of metastatic colorectal cancer.

4. Bevacizumab and Metastatic Colorectal Cancer {#Sec4}
===============================================

Bevacizumab improves overall survival in patients with metastatic colorectal cancer when used in conjunction with 5-FU-based chemotherapy regimens. The majority of studies were conducted prior to testing for the predictive markers discussed in section 2; however, subsequent analyses show that benefit with bevacizumab occurs irrespective of *KRAS*, *BRAF*, or *p53* status.\[[@CR40]\] A pooled analysis of phase II studies showed a median survival of 17.9 months in patients receiving 5-FU/leucovorin plus bevacizumab compared with 14.6 months with 5-FU/leucovorin or irinotecan (p = 0.008).\[[@CR8]\] In a pivotal study, the addition of bevacizumab to irinotecan as first-line therapy for metastatic colorectal cancer was associated with a significant increase in median overall survival, progression-free survival, and duration of response ([figure 2](#Fig2){ref-type="fig"}).\[[@CR7]\] In the BICC-C study, patients receiving FOLFIRI, modified irinotecan, or capecitabine plus irinotecan experienced median overall survival of 23.1, 17.6, and 18.9 months, respectively. A protocol change allowed for the addition of bevacizumab mid-trial, and in patients receiving this drug, median overall survival was not reached with FOLFIRI plus bevacizumab, but was reached at 19.2 months with modified irinotecan plus bevacizumab. No direct comparisons between regimens with or without bevacizumab were made.\[[@CR41]\] When bevacizumab was added to oxaliplatin-containing chemotherapy regimens, a significant improvement in progression-free survival (9.4 vs 8.0 months; p = 0.0023), but not overall survival (21.3 vs 19.9 months; p = 0.077), was seen.\[[@CR42]\] As second-line therapy in patients who had progressed on a non-bevacizumab-containing regimen, the addition of bevacizumab to oxaliplatin plus infusional 5-FU/leucovorin (FOLFOX) 4 was associated with a significant increase in overall survival (12.9 vs 10.8 months; p = 0.0011).\[[@CR43]\]

![Median overall survival, progression-free survival, and duration of response in 813 patients with previously untreated metastatic colorectal cancer treated with irinotecan plus bolus fluorouracil/leucovorin (IFL) and randomized to treatment with bevacizumab or placebo in a multicenter controlled study.\[[@CR7]\] \* p \< 0.001.](40268_2012_11020101_Fig2){#Fig2}

With respect to adverse events associated with bevacizumab, the elderly may experience an increased risk of stroke and other arterial events, and the drug is associated with impaired wound healing and, rarely, gastrointestinal perforation.\[[@CR14]\]

Patients with metastatic colorectal cancer that have progressed on a bevacizumab-containing regimen are a challenging proposition for the oncologist. Current guidelines suggest that these patients should be treated with an anti-EGFR monoclonal antibody; however, as discussed in section 2, these agents are only effective in patients with wild-type *KRAS*.\[[@CR14]\] The BOND-2 study was a phase II trial that investigated the administration of cetuximab and bevacizumab in patients with irinotecan-refractory colorectal cancer (n = 43) that were bevacizumab naïve.\[[@CR44]\] Overall survival was 14.5 months in the cetuximab/bevacizumab/irinotecan group versus 11.4 months in the cetuximab/bevacizumab group. In addition, time to tumor progression and response rates were 7.3 months and 37%, respectively, in the cetuximab/bevacizumab/irinotecan groups versus 4.9 months and 20% in patients who received cetuximab/bevacizumab. The toxicity profile of the cetuximab/bevacizumab/irinotecan combination is comparable with the toxicities seen with the individual agents.\[[@CR44]\] The CAIRO**-**2 study was a phase III trial of capecitabine, oxaliplatin plus bevacizumab, with or without cetuximab.\[[@CR45]\] A significant decrease in progression-free survival was observed in the cetuximab/bevacizumab arm versus the control arm (9.8 vs 10.7 months; p = 0.019). Diarrhea was the most frequent grade 3--4 toxicity, and an increase in skin toxicity was observed in the cetuximab/bevacizumab group.\[[@CR45]\]

The observational cohort BRiTE study showed that changing the chemotherapy regimen but continuing bevacizumab therapy after disease progression was associated with a significantly greater overall survival than continuing chemotherapy without bevacizumab (hazard ratio 0.48; p \< 0.001).\[[@CR46]\] While encouraging, these data are from an observational study and will need to be validated in an ongoing, prospective, randomized study.

5. Surgical Resection of Metastatic Disease and Perioperative Chemotherapy {#Sec5}
==========================================================================

Surgical resection offers the chance of long-term survival in patients who present with colorectal cancer and hepatic or pulmonary metastases, with a 25--35% rate of 5-year survival observed after complete resection.\[[@CR47]\] Important aspects of patient selection for surgical resection include the likelihood of achieving negative surgical margins and the maintenance of adequate liver reserve.\[[@CR14]\] The aim of surgical resection in this setting is curative, and the procedure should only be considered in patients in whom complete removal of known tumors is deemed possible.\[[@CR14]\] European guidelines recommend the use of perioperative chemotherapy in patients with resectable liver metastases, administered for 3 months before and 3 months after surgery.\[[@CR47]\] The use of perioperative FOLFOX4 improved 3-year progression-free survival by 7.3% in all randomized patients and by 9.2% in all patients undergoing resection in the European Organization for Research and Treatment of Cancer Intergroup trial 40983.\[[@CR48]\]

Initially, unresectable metastases may be rendered resectable following the administration of systemic chemotherapy with or without procedures of liver hypertrophy or embolization. Use of first-line combination chemotherapy in this setting has been shown to allow resection rates of up to 40% in patients who were not previously eligible for surgery.\[[@CR49]\] As discussed in section 4, the addition of bevacizumab to combination chemotherapy improves outcomes in patients with metastatic disease, and the use of this strategy prior to metastasectomy has increased. The safety of preoperative chemotherapy on surgical outcomes has been a matter of some concern, particularly with regard to wound-healing complications following preoperative bevacizumab therapy. However, a number of recent studies have shown that secondary resection following bevacizumab therapy is feasible, safe, and effective.\[[@CR50]--[@CR53]\] A nonrandomized study in which 56 patients with potentially curable metastatic colorectal cancer received preoperative treatment with capecitabine/oxaliplatin (XELOX) plus bevacizumab for six cycles with bevacizumab omitted for the final cycle showed no increases in the rate of surgical or wound-healing complications or bleeding severity with this regimen.\[[@CR51]\] Furthermore, neoadjuvant bevacizumab did not affect liver regeneration after resection.\[[@CR51]\] In the First BEAT, 225 of 1965 patients underwent curative hepatic metastasectomy, of whom complete resection with no residual disease was achieved in 173 patients.\[[@CR52]\] First BEAT collected safety data (primary endpoint) prospectively from patients undergoing surgery and hence, is the largest set of data using targeted therapy in this population. Patients in this study received fluoropyrimidine-based chemotherapy plus bevacizumab, with bevacizumab therapy ceasing a median of 64 days before surgery. A 2-year overall survival rate of 89% was seen in patients undergoing surgical resection with no residual disease.\[[@CR52]\] The incidence of grade 3 or 4 bleeding, wound-healing complications, and gastrointestinal perforation were 2.7%, 1.8%, and 2.2%, respectively, with no increase seen compared with historic controls.\[[@CR52]\] In the NO16966 trial (**s**tudy of Xeloda® \[capecitabine\] as a first-line therapy in patients with metastatic colorectal cancer), 1400 patients were randomized to receive XELOX or FOLFOX4 with or without bevacizumab in a 2 × 2 design.\[[@CR52]\] NO16966 was designed to demonstrate the non-inferiority of XELOX to FOLFOX4, and the data were collected retrospectively. Curative resection was performed in 44 patients randomized to bevacizumab and 34 patients receiving chemotherapy plus placebo. Two-year overall survival was 90.9% in bevacizumab recipients compared with 82.3% in those receiving placebo, but, more importantly, no increased incidence of bleeding, wound-healing complications, or gastrointestinal perforation was seen in bevacizumab recipients.\[[@CR52]\] In a study that included 219 patients, the addition of bevacizumab to FOLFOX as preoperative chemotherapy in patients undergoing hepatic resection produced a significant increase in response compared with FOLFOX alone.\[[@CR53]\] A major or complete pathologic response in patients receiving between one and eight cycles of chemotherapy occurred in 67% of patients receiving FOLFOX plus bevacizumab compared with 48% of FOLFOX recipients (p = 0.00017). A longer duration of preoperative chemotherapy was associated with a higher incidence of postoperative sinusoidal injury and liver insufficiency.\[[@CR53]\]

6. New Treatment Paradigms in Colorectal Cancer {#Sec6}
===============================================

The improvements in survival seen with the increased number of chemotherapeutic agents and the expanded ways in which these agents are used have brought about a changing paradigm for the treatment of colorectal cancer ([figure 3](#Fig3){ref-type="fig"}). In the past, metastatic colorectal cancer was treated with first-line therapy until progression, at which point treatment was switched to a regimen active in the second-line setting. This pattern was continued until patients had received all five active classes of drug, after which they were enrolled in clinical trials. The new approach to treatment views the choice of first and subsequent lines of treatment as a continuum rather than isolated choices. A patient's treatment may be changed prior to disease progression. Alternately, treatment may consist of aggressive treatment periods followed by breaks or maintenance therapy following treatment response. This approach to treatment may minimize the toxicity seen with individual agents.\[[@CR54]\] For example, oxaliplatin is associated with both acute and delayed sensory neuropathy, and a large proportion of patients receiving cumulative doses of oxaliplatin develop grade 3 cumulative neurotoxicity that may take several months to resolve.\[[@CR54]\] A balance between efficacy and toxicity was illustrated in the OPTIMOX 1 and 2 trials. In the OPTIMOX 1 trial, patients were randomized to FOLFOX4 every 2 weeks until disease progression or high-dose FOLFOX7 for six cycles followed by 5-FU/leucovorin for 12 cycles, after which they restarted FOLFOX7.\[[@CR55]\] Disease duration and overall survival was similar in each group, but patients receiving FOLFOX7 had a greatly reduced incidence of peripheral neuropathy, particularly during the later stages of treatment. To refine these data, the OPTIMOX 2 study randomized patients to six cycles of modified FOLFOX7 followed by 5-FU/leucovorin maintenance until progression, or six cycles of modified FOLFOX7 followed by cessation of therapy until tumor progression; in both groups, modified FOLFOX7 was reintroduced at disease progression.\[[@CR56]\] The duration of disease control and progression-free survival was significantly higher in patients receiving maintenance therapy, but the overall survival was similar in both groups. Therefore, although the authors of OPTIMOX 2 concluded that chemotherapy discontinuation could be safely considered in selected patients, these results suggest maintenance therapy in metastatic colorectal cancer is important, although its role is not yet clearly defined. As a final note on the future treatment of colorectal cancer, the cytostatic mechanism of action and relatively low toxicity make bevacizumab a suitable agent for use as maintenance therapy in colorectal cancer, as it is in non-small-cell lung cancer. An ongoing, randomized, phase III study investigating this use is currently ongoing and results are eagerly awaited to further help guide the use of bevacizumab in these patients.

![Suggested treatment continuums for metastatic colorectal cancer using (**a**) intensive or (**b**) less intensive therapy.\[[@CR54]\] **5-FU** = fluorouracil; **FOLFIRI** = irinotecan plus infusional fluorouracil/leucovorin; **FOLFOX** = oxaliplatin plus infusional fluorouracil/leucovorin; **LV** = leucovorin. \* indicates that cetuximab may be administered alone for patients intolerant to irinotecan. Reproduced from Goldberg et al.,\[[@CR54]\] copyright 2007, with permission of AlphaMed Press, Inc.](40268_2012_11020101_Fig3){#Fig3}

7. Conclusions {#Sec7}
==============

In contrast to 15 years ago, the oncologist is faced with a choice of treatments for patients with metastatic colorectal cancer and is able to predict survival of almost 2 years in these patients. Treatment should be tailored to the individual by using prognostic and predictive factors, including biomarkers. The use of these biomarkers can already assist with personalized treatment plans by, for example, identifying patients whose tumors will not respond to EGFR inhibitors, and this approach to patient care is anticipated to grow markedly in the future. Much work has been undertaken to investigate and better understand the tumor environment. The addition to chemotherapy of biologic agents such as bevacizumab that target angiogenesis, significantly improves the survival of patients with metastatic colorectal cancer independently of its biomarker status. Improved surgical techniques and use of chemotherapy plus biologic agents has also improved the odds of curative resection in patients with hepatic metastases. The prolonged survival seen with these advances in therapy has raised questions about adverse events seen with cumulative doses of chemotherapy agents and brought about new treatment paradigms, including the use of periods of intensive chemotherapy followed by drug holidays, and changing therapy early to avoid cumulative toxicity. These advances provide the platform to enable a personalized care plan formulated on an individual patient basis to further improve outcomes in metastatic colorectal cancer.
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